NYSE:SYK - Stryker Stock Price, Forecast & News

Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."

Stryker declared a quarterly dividend on Friday, February 7th. Investors of record on Tuesday, March 31st will be given a dividend of $0.575 per share on Thursday, April 30th. This represents a $2.30 annualized dividend and a yield of 1.02%. The ex-dividend date of this dividend is Monday, March 30th. View Stryker's Dividend History.

Stryker Co. (NYSE:SYK) released its quarterly earnings data on Tuesday, January, 28th. The medical technology company reported $2.49 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.46 by $0.03. The medical technology company earned $4.13 billion during the quarter, compared to the consensus estimate of $4.11 billion. Stryker had a net margin of 13.99% and a return on equity of 25.75%. The company's revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.18 EPS. View Stryker's Earnings History.

Stryker is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Stryker.

Stryker issued an update on its FY20 earnings guidance on Tuesday, January, 28th. The company provided EPS guidance of $9.00-9.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.04.

22 Wall Street analysts have issued 1 year target prices for Stryker's shares. Their forecasts range from $192.00 to $250.00. On average, they anticipate Stryker's stock price to reach $229.10 in the next twelve months. This suggests a possible upside of 2.1% from the stock's current price. View Analyst Price Targets for Stryker.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 6 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.

News headlines about SYK stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Stryker earned a news impact score of 1.3 on InfoTrie's scale. They also gave news headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Stryker.

Stryker saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,910,000 shares, an increase of 10.8% from the December 31st total of 3,530,000 shares. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is currently 2.9 days. Currently, 1.1% of the shares of the stock are short sold. View Stryker's Current Options Chain.

Some companies that are related to Stryker include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Insulet (PODD) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stryker investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Visa (V), Home Depot (HD), Medtronic (MDT), AbbVie (ABBV), Boeing (BA), NVIDIA (NVDA), Alibaba Group (BABA) and Abbott Laboratories (ABT).

Stryker's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Greenleaf Trust (5.74%), State Street Corp (3.66%), FMR LLC (2.91%), Capital Research Global Investors (2.54%), Bank of New York Mellon Corp (1.86%) and Franklin Resources Inc. (1.52%). Company insiders that own Stryker stock include Allan C Golston, Bijoy Sagar, David Floyd, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Roch Doliveux, Srikant M Datar, Timothy J Scannell and Yin C Becker. View Institutional Ownership Trends for Stryker.

SYK stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, FMR LLC, Capital International Investors, Alliancebernstein L.P., Massachusetts Financial Services Co. MA, Janus Henderson Group PLC, Jensen Investment Management Inc. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Stryker company stock in the last year include Allan C Golston, Bijoy Sagar, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Srikant M Datar, Timothy J Scannell and Yin C Becker. View Insider Buying and Selling for Stryker.

SYK stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Point72 Asset Management L.P., CWS Financial Advisors LLC, PGGM Investments, State Street Corp, Geode Capital Management LLC, Schroder Investment Management Group and GQG Partners LLC. View Insider Buying and Selling for Stryker.

Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYK stock can currently be purchased for approximately $224.47.

Stryker has a market capitalization of $84.08 billion and generates $14.88 billion in revenue each year. The medical technology company earns $2.08 billion in net income (profit) each year or $8.26 on an earnings per share basis. Stryker employs 40,000 workers across the globe.View Additional Information About Stryker.

The official website for Stryker is http://www.strykercorp.com/.

Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]